Enliven Shares Climb on Positive Leukemia Drug Trial Data
By Dean Seal
Enliven Therapeutics's shares jumped after the company released positive early data on the latest trial of its leukemia drug and said regulators green lit the design of a final large-scale study.
The stock was up 26% at $46.60 in premarket trading. Shares had already doubled year-to-date when the market closed Wednesday.
The clinical-stage biopharmaceutical company said before the opening bell that in the phase 1 clinical trial evaluating ELVN-001, its lead drug candidate, up to 61% of patients with previously treated chronic myeloid leukemia saw cancer markers drop significantly. Only 6% of patients stopped the treatment due to side effects.
Chief Medical Officer Helen Collins said the results were promising and showcase the consistency of ELVN-001's overall profile.
At the end of the trial, Enliven met with the Food and Drug Administration and reached an alignment with the agency on the planned daily dose and patient types to be used in a planned phase 3 trial.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 11, 2026 09:15 ET (13:15 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States